Dr. Shahrokh Shabahang is a co-founder and President of SEKRIS Biomedical, Inc, in Redlands, California. Pre-clinical studies have shown that our Apoptotic DNA Immunotherapy technology is effective for the treatment of immune-mediated inflammatory disorders. The strategy relies on the DNA-mediated induction of apoptotic cells. Apoptotic cell death is a naturally ongoing process within the human body, and one million cells die every second in an average human adult as a result. These dead cells are known to play a fundamental role in both establishing and maintaining peripheral immune tolerance. They not only serve as a source of self-antigens to maintain immune tolerance, but they also recruit antigen presenting cells, secrete anti-inflammatory cytokines, and display tolerogenic molecules.

Type 1 diabetes is the first target disease for the bench-to-bedside translation of SEKRIS technology... Current treatment for most patients consists of daily delivery of insulin as replacement therapy, but administration of the hormone does not completely prevent morbidity and mortality associated with the disease.  Consequently, there have been intense research efforts aiming at protecting or replacing beta-cell mass to restore physiological insulin delivery.   Our technology was developed in a model of type 1 diabetes from the very beginning and we now have a product candidate ready for production, Innovative New Drug-directed toxicology studies, and submission to the FDA for clinical trials >>>

Thanks to Bahman Javid